XOMA vs. VNDA, VSTM, MACK, RIGL, LXRX, RGLS, SYRS, EBS, CUE, and OPK
Should you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Merrimack Pharmaceuticals (MACK), Rigel Pharmaceuticals (RIGL), Lexicon Pharmaceuticals (LXRX), Regulus Therapeutics (RGLS), Syros Pharmaceuticals (SYRS), Emergent BioSolutions (EBS), Cue Biopharma (CUE), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
XOMA (NASDAQ:XOMA) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk.
Vanda Pharmaceuticals has a net margin of 1.30% compared to XOMA's net margin of -886.91%. Vanda Pharmaceuticals' return on equity of 0.46% beat XOMA's return on equity.
XOMA presently has a consensus price target of $74.00, indicating a potential upside of 191.22%. Given XOMA's higher probable upside, research analysts plainly believe XOMA is more favorable than Vanda Pharmaceuticals.
In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than XOMA. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 7 mentions for XOMA. Vanda Pharmaceuticals' average media sentiment score of 0.63 beat XOMA's score of 0.49 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.
XOMA has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.
Vanda Pharmaceuticals received 107 more outperform votes than XOMA when rated by MarketBeat users. Likewise, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 65.79% of users gave XOMA an outperform vote.
95.9% of XOMA shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 7.2% of XOMA shares are owned by insiders. Comparatively, 7.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Vanda Pharmaceuticals has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Vanda Pharmaceuticals beats XOMA on 13 of the 17 factors compared between the two stocks.
Get XOMA News Delivered to You Automatically
Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
